Gustave Roussy, Cancer Campus, Grand Paris
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Gustave Roussy, Cancer Campus, Grand Paris sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Gustave Roussy, Cancer Campus, Grand Paris: 3 sponsored US clinical trials, none currently recruiting.
Gustave Roussy, Cancer Campus, Grand Paris sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is B-cell Lymphoma, with 1 trials.
Upper-quartile sponsor footprint
Gustave Roussy, Cancer Campus, Grand Paris sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission
NCT00005062
Treatment of Mature B-cell Lymphoma/Leukaemia
NCT00162656
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
NCT00002823
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Therapeutic Areas
How the Gustave Roussy, Cancer Campus, Grand Paris archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: B-cell Lymphoma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Gustave Roussy, Cancer Campus, Grand Paris: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Gustave Roussy, Cancer Campus, Grand Paris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Gustave Roussy, Cancer Campus, Grand Paris page
3 registered trials is a research-attention snapshot, not an endorsement of Gustave Roussy, Cancer Campus, Grand Paris or any single study.
- None of Gustave Roussy, Cancer Campus, Grand Paris's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- B-cell Lymphoma is the condition Gustave Roussy, Cancer Campus, Grand Paris studies most, compare against other sponsors active in the same condition before evaluating a specific study. See B-cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gustave Roussy, Cancer Campus, Grand Paris pipeline card: 3 registered trials from official public datasets.Report a data error.